Joseph Ma

Title(s)Professor Of Clinical, School of Pharmacy and Pharmaceutical Science
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults. Int J Clin Pharmacol Ther. 2023 Jun; 61(6):262-269. Liyanage M, Blaquera CL, Piscitelli J, Penzak SR, Nolin TD, Paine MF, Ma JD. PMID: 37042268; PMCID: PMC10339714.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Fexofenadine Plasma Concentrations to Estimate Systemic Exposure in Healthy Adults Using a Limited Sampling Strategy with a Population Pharmacokinetic Approach. Ther Drug Monit. 2023 08 01; 45(4):539-545. Piscitelli J, Nikanjam M, Capparelli EV, Blaquera CL, Penzak SR, Nolin TD, Paine MF, Ma JD. PMID: 36645711; PMCID: PMC10123170.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    3. Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time. Eur J Clin Pharmacol. 2022 11; 78(11):1863-1864. Tung NP, Ma JD. PMID: 36098752; PMCID: PMC9546788.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    4. Spiritual AIM: assessment and documentation of spiritual needs in patients with cancer. J Health Care Chaplain. 2022 Oct-Dec; 28(4):566-577. Kestenbaum A, McEniry KA, Friedman S, Kent J, Ma JD, Roeland EJ. PMID: 34866556.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic Variability. Clin Pharmacokinet. 2021 08; 60(8):971-984. Tsunoda SM, Gonzales C, Jarmusch AK, Momper JD, Ma JD. PMID: 33959897; PMCID: PMC8332605.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    6. S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults. Eur J Clin Pharmacol. 2021 Sep; 77(9):1349-1356. Tran L, Nikanjam M, Capparelli EV, Bertino JS, Nafziger AN, Kashuba ADM, Turpault S, Ma JD. PMID: 33754183.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Exploring the Expanded Role of Pharmacists in Advance Care Planning. JCO Oncol Pract. 2021 02; 17(2):102-106. Ma JD, Dullea A, Hagmann C, Friedman S, Russell M, Cramer A, Benn M, Roeland EJ. PMID: 33417492; PMCID: PMC8462573.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study. Clin Transl Sci. 2020 09; 13(5):972-984. Jarmusch AK, Vrbanac A, Momper JD, Ma JD, Alhaja M, Liyanage M, Knight R, Dorrestein PC, Tsunoda SM. PMID: 32216086; PMCID: PMC7485946.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    9. Advancing Pharmacist Collaborative Care within Academic Health Systems. Pharmacy (Basel). 2019 Oct 11; 7(4). Awdishu L, Singh RF, Saunders I, Yam FK, Hirsch JD, Lorentz S, Atayee RS, Ma JD, Tsunoda SM, Namba J, Mnatzaganian CL, Painter NA, Watanabe JH, Lee KC, Daniels CD, Morello CM. PMID: 31614555; PMCID: PMC6958419.
      View in: PubMed   Mentions: 9  
    10. More opioids, more constipation? Evaluation of longitudinal total oral opioid consumption and self-reported constipation in patients with cancer. Support Care Cancer. 2020 Apr; 28(4):1793-1797. Roeland EJ, Sera CJ, Ma JD. PMID: 31332514.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    11. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults. J Clin Pharmacol. 2019 11; 59(11):1495-1504. Yang J, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Stoch SA, Bertino JS, Nafziger AN, Ma JD. PMID: 31051051.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults. Ther Drug Monit. 2018 12; 40(6):754-758. Lin S, Nikanjam M, Capparelli EV, Allegrini A, Pavone D, Yim DS, Hammami MM, Bertino JS, Nafziger AN, Park YS, Kang JS, Yin OQ, Ma JD. PMID: 30045358; PMCID: PMC6237623.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Opioid and Benzodiazepine Relative Use in Breast Cancer Patients Before, During, and After Curative Chemotherapy. J Pain Palliat Care Pharmacother. 2018 Mar; 32(1):27-29. Yau WH, Roeland EJ, Revta C, Ale-Ali A, Ma JD. PMID: 30204508.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    14. Evidence-based Palliative Care Approaches to Non-pain Physical Symptom Management in Cancer Patients. Semin Oncol Nurs. 2018 08; 34(3):227-240. Hagmann C, Cramer A, Kestenbaum A, Durazo C, Downey A, Russell M, Geluz J, Ma JD, Roeland EJ. PMID: 30120000.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    15. Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach. J Clin Pharmacol. 2018 09; 58(9):1205-1213. Yang J, Patel M, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Aubrey Stoch S, Bertino JS, Nafziger AN, Ma JD. PMID: 29663428.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    16. Pain Syndromes and Management in Adult Hematopoietic Stem Cell Transplantation. Hematol Oncol Clin North Am. 2018 06; 32(3):551-567. Ma JD, El-Jawahri AR, LeBlanc TW, Roeland EJ. PMID: 29729788.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    17. Transfusion practices at end of life for hematopoietic stem cell transplant patients. Support Care Cancer. 2018 Jun; 26(6):1927-1931. Wang WS, Ma JD, Nelson SH, Revta C, Buckholz GT, Mulroney C, Roeland EJ. PMID: 29285557; PMCID: PMC5924436.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Advance Care Planning and Palliative Care Integration for Patients Undergoing Hematopoietic Stem-Cell Transplantation. J Oncol Pract. 2017 09; 13(9):e721-e728. Wang WS, Ma JD, Nelson SH, Revta C, Buckholz GT, Mulroney CM, Roeland EJ. PMID: 28644706; PMCID: PMC6366810.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    19. Cancer Cachexia: Beyond Weight Loss. J Oncol Pract. 2016 11; 12(11):1163-1171. Bruggeman AR, Kamal AH, LeBlanc TW, Ma JD, Baracos VE, Roeland EJ. PMID: 27858548.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    20. Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials. Support Care Cancer. 2017 02; 25(2):365-369. Roeland EJ, Ma JD, Nelson SH, Seibert T, Heavey S, Revta C, Gallivan A, Baracos VE. PMID: 27628947.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    21. The Default Dilemma: Code Status Regardless of Medical Context. J Palliat Med. 2016 11; 19(11):1134. Kronenberg DG, Hagmann CH, Ma JD, Revta C, Armstrong J, Roeland EJ. PMID: 27500355.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans. J Clin Pharmacol. 2016 07; 56 Suppl 7:S82-98. Momper JD, Tsunoda SM, Ma JD. PMID: 27385182.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    23. S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction. Ther Drug Monit. 2016 06; 38(3):383-7. Chang AT, Bertino JS, Nafziger AN, Kashuba AD, Turpault S, Lewis LD, Ma JD. PMID: 26818625.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    24. Exploring the Definition of an Informed Health Care Proxy. J Palliat Med. 2016 Mar; 19(3):250-1. Ma JD, Benn M, Nelson SH, Campillo A, Heavey SF, Cramer A, Revta C, Thornberry K, Roeland EJ. PMID: 26836962.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    25. A Case-Based Approach to Integrating Opioid Pharmacokinetic and Pharmacodynamic Concepts in Cancer Pain Management. J Clin Pharmacol. 2016 07; 56(7):785-93. Lam LH, Pirrello RD, Ma JD. PMID: 26626053.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    26. Retrospective analysis of pharmacist interventions in an ambulatory palliative care practice. J Oncol Pharm Pract. 2016 Dec; 22(6):757-765. Ma JD, Tran V, Chan C, Mitchell WM, Atayee RS. PMID: 26428283.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    27. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care. J Pain Palliat Care Pharmacother. 2015 Sep; 29(3):247-60. Chang A, Roeland EJ, Atayee RS, Revta C, Ma JD. PMID: 26368648.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    28. Variable Patterns of Continuous Morphine Infusions at End of Life. J Palliat Med. 2015 Sep; 18(9):786-9. Lin KJ, Ching A, Edmonds KP, Roeland EJ, Revta C, Ma JD, Atayee RS. PMID: 26107143; PMCID: PMC4553381.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    29. Olanzapine in the treatment of refractory nausea and vomiting: a case report and review of the literature. J Pain Palliat Care Pharmacother. 2015 Jun; 29(2):148-52. Langley-DeGroot M, Ma JD, Hirst J, Roeland EJ. PMID: 26095486.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    30. Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping. Ther Drug Monit. 2015 Feb; 37(1):84-9. Masters JC, Harano DM, Greenberg HE, Tsunoda SM, Jang IJ, Ma JD. PMID: 25004135; PMCID: PMC4282980.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    31. Lack of documentation of evidence-based prognostication in cancer patients by inpatient palliative care consultants. J Palliat Med. 2015 Apr; 18(4):382-5. Bruggeman AR, Heavey SF, Ma JD, Revta C, Roeland EJ. PMID: 25608220.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    32. Evaluation of a shared pharmacogenomics curriculum for pharmacy students. Pharmacogenomics. 2015; 16(4):315-22. Lee KC, Hudmon KS, Ma JD, Kuo GM. PMID: 25823780.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    33. Response to urine drug testing for oxycodone and its metabolites as a tool for drug-drug interactions. J Anal Toxicol. 2015 Jan-Feb; 39(1):80. Elder NM, Atayee RS, Best BM, Ma JD. PMID: 25288719.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. Authors' reply. J Anal Toxicol. 2014 Sep; 38(7):463. Elder NM, Atayee RS, Best BM, Ma JD. PMID: 24986838.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. Evaluation of concomitant methylphenidate and opioid use in patients with pain. J Anal Toxicol. 2014 Sep; 38(7):421-6. Jiang JY, Best BM, Morello CM, Atayee RS, Ma JD. PMID: 24907143.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. Urinary hydrocodone and metabolite distributions in pain patients. J Anal Toxicol. 2014 Sep; 38(7):404-9. Barakat NH, Atayee RS, Best BM, Ma JD. PMID: 24836897.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    37. Urine specimen detection of zolpidem use in patients with pain. J Anal Toxicol. 2014 Jul-Aug; 38(6):322-6. Mann LM, Atayee RS, Best BM, Morello CM, Ma JD. PMID: 24802157.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    38. Observations on hydrocodone and its metabolites in oral fluid specimens of the pain population: comparison with urine. J Opioid Manag. 2014 May-Jun; 10(3):177-86. Cao JM, Ma JD, Morello CM, Atayee RS, Best BM. PMID: 24944068.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. Variability in metabolism of imipramine and desipramine using urinary excretion data. J Anal Toxicol. 2014 Jul-Aug; 38(6):368-74. Ramey K, Ma JD, Best BM, Atayee RS, Morello CM. PMID: 24782142.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    40. Novel investigational biologics for the treatment of cancer cachexia. Expert Opin Biol Ther. 2014 Aug; 14(8):1113-20. Ma JD, Heavey SF, Revta C, Roeland EJ. PMID: 24707881.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    41. Naltrexone metabolism and concomitant drug concentrations in chronic pain patients. J Anal Toxicol. 2014 May; 38(4):212-7. Liu JC, Ma JD, Morello CM, Atayee RS, Best BM. PMID: 24659754.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    42. Observation of improved adherence with frequent urine drug testing in patients with pain. J Opioid Manag. 2014 Mar-Apr; 10(2):111-8. Yee DA, Hughes MM, Guo AY, Barakat NH, Tse SA, Ma JD, Best BM, Atayee RS. PMID: 24715666.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    43. Observations of urinary oxycodone and metabolite distributions in pain patients. J Anal Toxicol. 2014 Apr; 38(3):129-34. Elder NM, Atayee RS, Best BM, Ma JD. PMID: 24523296.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    44. Urinary diazepam metabolite distribution in a chronic pain population. J Anal Toxicol. 2014 Apr; 38(3):135-42. Luk S, Atayee RS, Ma JD, Best BM. PMID: 24500275.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    45. Factors affecting carisoprodol metabolism in pain patients using urinary excretion data. J Anal Toxicol. 2014 Apr; 38(3):122-8. Tse SA, Atayee RS, Ma JD, Best BM. PMID: 24488112.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. A single-center, retrospective analysis evaluating the utilization of the opioid risk tool in opioid-treated cancer patients. J Pain Palliat Care Pharmacother. 2014 Mar; 28(1):4-9. Ma JD, Horton JM, Hwang M, Atayee RS, Roeland EJ. PMID: 24417217.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    47. Observations on the urine metabolic profile of codeine in pain patients. J Anal Toxicol. 2014 Mar; 38(2):86-91. Yee DA, Atayee RS, Best BM, Ma JD. PMID: 24396053.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    48. Monitoring oxycodone use in patients with chronic pain: analysis of oxycodone and metabolite excretion in saliva and urine. J Opioid Manag. 2014 Jan-Feb; 10(1):47-56. Moy KV, Ma JD, Morello CM, Atayee RS, Best BM. PMID: 24604569.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    49. Tricyclic antidepressants: is your patient taking them? Observations on adherence and unreported use using prescriber-reported medication lists and urine drug testing. Pain Med. 2014 Mar; 15(3):355-63. Bordson SJ, Atayee RS, Ma JD, Best BM. PMID: 24308804.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    50. Endogenous 4β-hydroxycholesterol-to-cholesterol ratio is not a validated biomarker for the assessment of CYP3A activity. Drug Metab Dispos. 2013 Nov; 41(11):1972. Ma JD, Nafziger AN, Bertino JS. PMID: 24131962.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    51. Factors impacting variability of the urinary normeperidine-to-meperidine metabolic ratio in patients with chronic pain. J Anal Toxicol. 2014 Jan-Feb; 38(1):1-7. Moy KV, Ma JD, Best BM, Atayee RS. PMID: 24133175.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    52. Urine specimen detection of concurrent nonprescribed medicinal and illicit drug use in patients prescribed buprenorphine. J Anal Toxicol. 2013 Nov-Dec; 37(9):636-41. Guo AY, Ma JD, Best BM, Atayee RS. PMID: 24080973.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    53. A massive open online course on pharmacogenomics: not just disruptive innovation but a possible solution. Pharmacogenomics. 2013 Jul; 14(10):1125-7. Ma JD, Lee KC, Kuo GM. PMID: 23859565.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    54. Implementation and outcomes of a live continuing education program on pharmacogenomics. Pharmacogenomics. 2013 Jun; 14(8):885-95. Kuo GM, Lee KC, Ma JD. PMID: 23746183.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    55. Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping. Drug Metabol Drug Interact. 2013; 28(4):217-23. Tai W, Gong SL, Tsunoda SM, Greenberg HE, Gorski JC, Penzak SR, Stoch SA, Ma JD. PMID: 24114901.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    56. A train-the-trainer approach to a shared pharmacogenomics curriculum for US colleges and schools of pharmacy. Am J Pharm Educ. 2012 Dec 12; 76(10):193. Lee KC, Ma JD, Hudmon KS, Kuo GM. PMID: 23275658; PMCID: PMC3530055.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    57. Validating phenotyping cocktails: more work needs to be done. J Clin Pharmacol. 2012 Nov; 52(11):1772-3; author reply 1774-5. Ma JD, Nafziger AN, Bertino JS. PMID: 23105127.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    58. Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation. Int J Clin Pharmacol Ther. 2012 Jul; 50(7):468-75. Nguyen AN, Hoffman JT, Tsunoda SM, Jang IJ, Ma JD. PMID: 22541751.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    59. Clinical application of pharmacogenomics. J Pharm Pract. 2012 Aug; 25(4):417-27. Ma JD, Lee KC, Kuo GM. PMID: 22689709.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    60. Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity. Drug Metab Lett. 2012 Jun 01; 6(2):94-101. Wu JC, Nafziger AN, Bertino JS, Ma JD. PMID: 22594566.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    61. Preliminary analysis of midlevel practitioners on pain and health-related quality of life and function for a palliative care service at a comprehensive cancer center. J Palliat Med. 2012 Apr; 15(4):388-9. Hansen PR, Ma JD, Atayee RS. PMID: 22500477.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    62. Denosumab for treatment of breast cancer bone metastases and beyond. Expert Opin Biol Ther. 2012 Apr; 12(4):491-501. Nangia JR, Ma JD, Nguyen CM, Mendes MA, Trivedi MV. PMID: 22348344.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    63. Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping. Eur J Clin Pharmacol. 2012 Apr; 68(4):407-13. Lawson EB, Wu JC, Baldwin RM, Ingelman-Sundberg M, Rosenborg S, Yim DS, Yin OQ, Capparelli EV, Ma JD. PMID: 22009190.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    64. Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk. PLoS Curr. 2011 May 15; 3:RRN1236. Nguyen CM, Mendes MA, Ma JD. PMID: 21593964; PMCID: PMC3094768.
      View in: PubMed   Mentions: 20  
    65. Institutional Profile: University of California San Diego Pharmacogenomics Education Program (PharmGenEd™): bridging the gap between science and practice. Pharmacogenomics. 2011 Feb; 12(2):149-53. Kuo GM, Ma JD, Lee KC, Halpert JR, Bourne PE, Ganiats TG, Taylor P. PMID: 21332308.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    66. Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virus. PLoS Curr. 2011 Jan 08; 3:RRN1207. Nguyen CM, Mendes M, Tsunoda S, Ma JD. PMID: 21278901; PMCID: PMC3024597.
      View in: PubMed   Mentions: 2  
    67. HLA-B*5701 testing to predict abacavir hypersensitivity. PLoS Curr. 2010 Dec 07; 2:RRN1203. Ma JD, Lee KC, Kuo GM. PMID: 21151380; PMCID: PMC3000684.
      View in: PubMed   Mentions: 24  
    68. Evaluation of current and upcoming therapies in oral mucositis prevention. Future Oncol. 2010 Nov; 6(11):1751-70. Wu JC, Beale KK, Ma JD. PMID: 21142661.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    69. Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. Clin Pharmacokinet. 2010 Apr; 49(4):223-37. Ma JD, Tsunoda SM, Bertino JS, Trivedi M, Beale KK, Nafziger AN. PMID: 20214407.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    70. Pharmacogenomics: bridging the gap between science and practice. J Am Pharm Assoc (2003). 2010 Jan-Feb; 50(1):e1-14; quiz e15-7. Lee KC, Ma JD, Kuo GM. PMID: 20368146.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    71. Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping. Br J Clin Pharmacol. 2009 Mar; 67(3):374-5. Ma JD, Nafziger AN, Mylott W, Haughey DB, Rocci ML, Bertino JS. PMID: 19220276; PMCID: PMC2675050.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    72. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer. Future Oncol. 2008 Aug; 4(4):483-500. Trivedi M, Budihardjo I, Loureiro K, Reid TR, Ma JD. PMID: 18684060.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    73. Quantitative assessment of hepatic blood flow using intravenous indocyanine green. Eur J Clin Pharmacol. 2008 Nov; 64(11):1133-4. Ma JD, Nafziger AN, Mylott W, Haughey DB, Rocci ML, Bertino JS. PMID: 18594801.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    74. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006 Apr; 50(4):1130-5. Ma JD, Nafziger AN, Villano SA, Gaedigk A, Bertino JS. PMID: 16569820; PMCID: PMC1426970.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    75. Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. Drug Metab Dispos. 2006 May; 34(5):783-5. Ma JD, Nafziger AN, Rhodes G, Liu S, Bertino JS. PMID: 16467135.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    76. The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe. J Clin Pharmacol. 2006 Jan; 46(1):103-8. Ma JD, Nafziger AN, Rhodes G, Liu S, Gartung AM, Bertino JS. PMID: 16397289.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    77. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers. J Clin Pharmacol. 2004 Jun; 44(6):570-6. Ma JD, Nafziger AN, Kashuba AD, Kim MJ, Gaedigk A, Rowland E, Kim JS, Bertino JS. PMID: 15145963.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    78. Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers. J Clin Pharmacol. 2004 May; 44(5):447-56. Ma JD, Nafziger AN, Bertino JS. PMID: 15102864.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    Joseph's Networks
    Concepts (311)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (24)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California